

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	3.9	155.5	(56.8-338.6)	Male	3	2.1	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	18	16.5	109.0	(64.5-172.2)	Female	4	2.0	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	0.8	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Colon / Rectum					Female	0	0.8	nc	(nc-nc)
Male	8	6.0	133.5	(57.5-263.1)	Ovary				
Female	3	6.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	3	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	5	1.3	374.4	(120.6-873.6)
Hodgkin Lymphoma					Prostate				
Male	0	0.3	nc	(nc-nc)	Male	18	16.0	112.5	(66.7-177.9)
Female	2	0.3	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	2	1.0	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Testis				
Larynx					Male	0	0.6	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)					

Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	4	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Lung and Bronchus				
Male	11	7.7	143.8	(71.7-257.3)
Female	7	7.4	94.6	(37.9-194.9)

Thyroid

Male	1	0.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	3	3.2	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	70	52.7	132.8	(103.6-167.8)
Female	60	53.7	111.7	(85.3-143.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

232

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	1	5.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
	Male	3	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Esophagus	Female	3	1.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis	Female	1	0.1	nc	(nc-nc)	Male	5	6.0	83.2	(26.8-194.3)
	Male	2	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Larynx	Female	1	0.4	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
	Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Leukemia	Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Male	2	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Male	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Lung and Bronchus	Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Male	2	2.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
	Female	1	2.1	nc	(nc-nc)	Male	20	20.2	99.1	(60.5-153.1)
						Female	12	17.2	69.9	(36.1-122.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

233
Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	7.9	88.4	(35.4-182.1)	Male	4	4.1	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	1.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
Female	21	32.0	65.5	(40.5-100.2)	Female	4	3.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	1.5	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Colon / Rectum					Female	2	1.6	nc	(nc-nc)
Male	5	12.2	40.8	(13.2-95.3)	Ovary				
Female	13	12.7	102.3	(54.4-174.9)	Female	5	3.3	152.4	(49.1-355.7)
Esophagus					Pancreas				
Male	2	1.9	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.7	nc	(nc-nc)	Male	24	32.7	73.4	(47.0-109.2)
Female	1	0.6	nc	(nc-nc)	Stomach				
Kidney & Renal Pelvis					Male	1	2.1	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)					

Larynx	Female	2	2.2	nc	(nc-nc)	Testis	Female	0	1.3	nc	(nc-nc)
	Male	2	1.4	nc	(nc-nc)		Male	2	1.1	nc	(nc-nc)
Leukemia	Female	0	0.4	nc	(nc-nc)	Thyroid					
	Male	2	2.5	nc	(nc-nc)		Male	2	0.8	nc	(nc-nc)
	Female	2	2.2	nc	(nc-nc)		Female	4	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	3	1.5	nc	(nc-nc)						
	Female	0	0.6	nc	(nc-nc)		Female	5	6.3	79.7	(25.7-186.0)
Lung and Bronchus						All Sites / Types					
	Male	10	15.8	63.5	(30.4-116.8)		Male	80	107.1	74.7	(59.2-93.0)
	Female	11	14.3	77.0	(38.4-137.8)		Female	96	105.1	91.3	(74.0-111.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

234
Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	24	15.6	153.6	(98.4-228.5)	Male	11	6.4	171.8	(85.6-307.4)
Female	8	5.5	145.6	(62.7-286.9)	Female	11	4.3	254.0	(126.6-454.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				

Male	1	0.4	nc	(nc-nc)
Female	69	46.4	148.7	(115.7-188.1)
Cervix Uteri				
Female	1	1.6	nc	(nc-nc)
Colon / Rectum				
Male	19	23.4	81.2	(48.9-126.8)
Female	26	22.9	113.6	(74.2-166.5)
Esophagus				
Male	3	3.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	5.2	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)
Larynx				
Male	3	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	6	4.1	148.1	(54.1-322.3)
Female	4	3.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	2.4	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Lung and Bronchus				
Male	19	29.7	64.0	(38.5-100.0)
Female	28	24.5	114.5	(76.1-165.5)

Male	6	6.6	90.7	(33.1-197.4)
Female	14	6.2	224.3	(122.5-376.4)
Oral Cavity & Pharynx				
Male	2	4.7	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)
Ovary				
Female	2	4.9	nc	(nc-nc)
Pancreas				
Male	2	4.3	nc	(nc-nc)
Female	5	4.8	103.6	(33.4-241.9)
Prostate				
Male	102	59.2	172.3	(140.5-209.2)
Stomach				
Male	3	4.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)
Testis				
Male	1	0.7	nc	(nc-nc)
Thyroid				
Male	0	0.9	nc	(nc-nc)
Female	5	2.4	210.5	(67.8-491.2)
Uteri Corpus and Uterus, NOS				
Female	11	9.5	115.9	(57.8-207.4)
All Sites / Types				
Male	221	190.9	115.8	(101.0-132.1)
Female	213	164.7	129.3	(112.6-147.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

235
Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.6	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	4	5.4	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Colon / Rectum					Female	0	0.3	nc	(nc-nc)
Male	4	2.5	nc	(nc-nc)	Ovary				
Female	1	1.8	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	5	7.1	70.2	(22.6-163.8)
Female	0	0.1	nc	(nc-nc)					

Kidney & Renal Pelvis						Stomach				
	Male	0	0.7	nc	(nc-nc)		Male	1	0.4	nc (nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Larynx						Testis				
	Male	2	0.3	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.5	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	1	0.3	nc	(nc-nc)		Female	0	0.4	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.3	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)		Female	1	1.1	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	3	3.3	nc	(nc-nc)		Male	20	22.6	88.4 (54.0-136.6)
	Female	3	2.2	nc	(nc-nc)		Female	14	16.7	83.8 (45.8-140.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

236
Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
	Male	14	12.2	114.6 (62.6-192.3)		Male	5	6.7	75.0 (24.2-175.1)
	Female	7	4.5	155.8 (62.4-321.0)		Female	4	5.6	nc (nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
	Male	3	2.6	nc (nc-nc)		Male	2	1.7	nc (nc-nc)

Breast	Female	4	2.2	nc	(nc-nc)
	Male	0	0.4	nc	(nc-nc)
Cervix Uteri	Female	54	51.4	105.1	(78.9-137.1)
	Male				
Colon / Rectum	Female	3	2.6	nc	(nc-nc)
	Male	15	19.0	78.9	(44.1-130.1)
Esophagus	Female	11	18.1	60.9	(30.3-108.9)
	Male	2	3.0	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.9	nc	(nc-nc)
	Male	2	1.2	nc	(nc-nc)
Kidney & Renal Pelvis	Female	0	1.0	nc	(nc-nc)
	Male	10	5.1	195.1	(93.4-358.9)
Larynx	Female	3	3.4	nc	(nc-nc)
	Male	1	2.3	nc	(nc-nc)
Leukemia	Female	1	0.6	nc	(nc-nc)
	Male	6	4.0	150.6	(55.0-327.9)
Liver and Intrahepatic Bile Ducts	Female	1	3.3	nc	(nc-nc)
	Male	3	2.4	nc	(nc-nc)
Lung and Bronchus	Female	0	0.9	nc	(nc-nc)
	Male				

Non-Hodgkin Lymphoma	Female	0	1.4	nc	(nc-nc)
	Male	4	6.5	nc	(nc-nc)
Oral Cavity & Pharynx	Female	5	5.8	85.5	(27.6-199.6)
	Male	5	5.0	100.1	(32.3-233.6)
Ovary	Female	2	2.4	nc	(nc-nc)
	Male				
Pancreas	Female	6	5.2	115.9	(42.3-252.3)
	Male	3	3.6	nc	(nc-nc)
Prostate	Female	6	3.7	160.8	(58.7-350.0)
	Male	42	50.4	83.4	(60.1-112.7)
Stomach	Female	1	1.9	nc	(nc-nc)
	Male	4	3.2	nc	(nc-nc)
Testis	Female				
	Male	3	2.1	nc	(nc-nc)
Thyroid	Female	6	4.6	131.5	(48.0-286.2)
	Male	0	1.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS	Female	7	9.9	70.6	(28.3-145.4)
	Male				
All Sites / Types					

Male	30	24.1	124.4	(83.9-177.7)
Female	17	21.3	79.7	(46.4-127.7)

Male	167	167.9	99.4	(84.9-115.7)
Female	152	161.9	93.9	(79.6-110.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

237
Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	18	13.6	132.4	(78.4-209.3)	Male	4	6.9	nc	(nc-nc)
Female	6	5.5	108.6	(39.6-236.3)	Female	4	5.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	2.6	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	3	6.8	nc	(nc-nc)
Female	58	54.6	106.2	(80.6-137.3)	Female	3	6.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	3	2.5	nc	(nc-nc)	Male	9	5.0	178.4	(81.4-338.7)
					Female	3	2.7	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	22	20.9	105.3	(66.0-159.4)					
Female	30	22.9	131.2	(88.5-187.3)	Female	7	5.6	124.4	(49.8-256.4)
Esophagus					Pancreas				
Male	4	3.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	3	4.8	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	0	1.1	nc	(nc-nc)	Male	58	53.8	107.8	(81.9-139.4)
Female	2	1.0	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	6	5.3	112.2	(41.0-244.3)	Male	8	3.6	225.0	(96.9-443.3)
Female	5	3.8	130.7	(42.1-304.9)	Female	4	2.4	nc	(nc-nc)
Larynx					Testis				
Male	3	2.4	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	3	4.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	4	3.8	nc	(nc-nc)	Female	4	4.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	2.5	200.6	(64.6-468.1)					
Female	1	1.1	nc	(nc-nc)	Female	18	10.6	170.0	(100.7-268.7)
Lung and Bronchus					All Sites / Types				
Male	35	26.5	132.2	(92.0-183.8)	Male	198	179.8	110.1	(95.3-126.6)
Female	23	25.0	92.0	(58.3-138.1)	Female	196	182.6	107.3	(92.8-123.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

238
Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	5.5	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)

Brain and Other Nervous System	Female	2	1.7	nc	(nc-nc)
	Male	0	1.0	nc	(nc-nc)
Breast	Female	1	0.8	nc	(nc-nc)
	Male	0	0.2	nc	(nc-nc)
	Female	13	18.9	68.8	(36.6-117.7)
Cervix Uteri					
	Female	0	0.8	nc	(nc-nc)
Colon / Rectum					
	Male	3	8.5	nc	(nc-nc)
	Female	4	6.8	nc	(nc-nc)
Esophagus					
	Male	2	1.3	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma					
	Male	0	0.4	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis					
	Male	5	2.2	229.1	(73.8-534.7)
	Female	2	1.3	nc	(nc-nc)
Larynx					
	Male	1	1.0	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)
Leukemia					
	Male	2	1.7	nc	(nc-nc)
	Female	2	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					

Multiple Myeloma	Female	3	1.9	nc	(nc-nc)
	Male	0	0.8	nc	(nc-nc)
	Female	0	0.5	nc	(nc-nc)
Non-Hodgkin Lymphoma					
	Male	3	2.7	nc	(nc-nc)
	Female	0	2.2	nc	(nc-nc)
Oral Cavity & Pharynx					
	Male	1	2.1	nc	(nc-nc)
	Female	0	0.9	nc	(nc-nc)
Ovary					
	Female	1	1.9	nc	(nc-nc)
Pancreas					
	Male	1	1.6	nc	(nc-nc)
	Female	1	1.4	nc	(nc-nc)
Prostate					
	Male	15	22.8	65.7	(36.7-108.3)
Stomach					
	Male	3	1.4	nc	(nc-nc)
	Female	0	0.7	nc	(nc-nc)
Testis					
	Male	2	0.6	nc	(nc-nc)
Thyroid					
	Male	0	0.5	nc	(nc-nc)
	Female	3	1.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS					

	Male	0	1.0	nc	(nc-nc)				
	Female	0	0.3	nc	(nc-nc)	Female	4	3.8	nc (nc-nc)
Lung and Bronchus						All Sites / Types			
	Male	9	11.0	82.0	(37.4-155.7)	Male	57	73.7	77.3 (58.5-100.2)
	Female	2	8.3	nc	(nc-nc)	Female	42	60.1	69.9 (50.4-94.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

239 Peabody Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	70	60.3	116.2	(90.6-146.8)	Male	27	29.8	90.5	(59.6-131.7)
Female	35	23.4	149.7	(104.3-208.2)	Female	24	24.0	100.1	(64.1-148.9)
Brain and Other Nervous System					Multiple Myeloma				
Male	6	11.1	54.2	(19.8-118.0)	Male	8	8.4	95.5	(41.1-188.3)
Female	8	9.7	82.5	(35.5-162.6)	Female	10	7.3	136.6	(65.4-251.2)
Breast					Non-Hodgkin Lymphoma				
Male	1	1.8	nc	(nc-nc)	Male	35	29.5	118.5	(82.6-164.9)
Female	262	233.8	112.1	(98.9-126.5)	Female	38	28.5	133.3	(94.3-182.9)
Cervix Uteri					Oral Cavity & Pharynx				
Female	14	10.3	135.7	(74.1-227.8)	Male	24	22.5	106.6	(68.3-158.6)
					Female	8	11.5	69.7	(30.0-137.4)
Colon / Rectum					Ovary				
Male	96	92.7	103.5	(83.8-126.4)					
Female	110	95.0	115.8	(95.2-139.6)	Female	24	23.9	100.2	(64.2-149.1)

Esophagus					Pancreas				
Male	15	14.6	102.5	(57.3-169.1)	Male	22	17.2	127.8	(80.1-193.5)
Female	2	4.7	nc	(nc-nc)	Female	25	19.8	126.0	(81.5-186.0)
Hodgkin Lymphoma					Prostate				
Male	8	4.5	177.2	(76.3-349.2)	Male	242	250.3	96.7	(84.9-109.7)
Female	2	3.9	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	20	23.8	84.1	(51.4-130.0)	Male	16	15.6	102.5	(58.5-166.4)
Female	16	16.4	97.5	(55.7-158.3)	Female	15	10.0	150.1	(84.0-247.6)
Larynx					Testis				
Male	10	10.9	92.1	(44.1-169.5)	Male	9	7.6	119.0	(54.3-226.0)
Female	2	3.0	nc	(nc-nc)					
Leukemia					Thyroid				
Male	22	18.0	122.5	(76.8-185.5)	Male	6	5.5	109.2	(39.9-237.8)
Female	22	15.6	141.1	(88.4-213.6)	Female	21	17.2	122.4	(75.7-187.1)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	9	11.0	81.9	(37.4-155.4)					
Female	6	4.5	134.3	(49.0-292.3)	Female	57	46.7	122.1	(92.5-158.2)
Lung and Bronchus					All Sites / Types				
Male	141	119.4	118.1	(99.4-139.2)	Male	836	805.8	103.7	(96.8-111.0)
Female	118	108.3	109.0	(90.2-130.5)	Female	884	774.1	114.2	(106.8-122.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	6.2	81.0	(26.1-189.1)	Female	2	0.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
					Female	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	1	2.7	nc	(nc-nc)					
Female	1	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	11	7.4	148.3	(73.9-265.4)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	1	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Larynx					Testis				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				

Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	3	3.5	nc	(nc-nc)	Male	22	23.6	93.1	(58.3-140.9)
Female	0	2.4	nc	(nc-nc)	Female	13	18.4	70.5	(37.5-120.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

241 Pembroke									
Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002									
	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	23	13.3	173.4	(109.9-260.1)	Male	12	7.8	153.3	(79.1-267.8)
Female	2	4.6	nc	(nc-nc)	Female	10	6.5	154.8	(74.1-284.6)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	3.2	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	8	2.5	314.8	(135.5-620.2)	Female	3	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	9	7.5	119.8	(54.7-227.4)
Female	68	59.0	115.3	(89.5-146.1)	Female	6	6.2	96.4	(35.2-209.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	3.0	nc	(nc-nc)	Male	5	6.2	80.8	(26.0-188.6)
					Female	5	2.7	186.6	(60.1-435.4)

Colon / Rectum					Ovary				
Male	12	21.1	57.0	(29.4-99.5)					
Female	11	18.2	60.4	(30.1-108.1)	Female	7	5.9	119.5	(47.9-246.2)
Esophagus					Pancreas				
Male	5	3.6	140.1	(45.1-326.9)	Male	7	4.0	175.4	(70.3-361.5)
Female	0	0.9	nc	(nc-nc)	Female	6	3.7	161.2	(58.9-350.9)
Hodgkin Lymphoma					Prostate				
Male	3	1.4	nc	(nc-nc)	Male	58	60.3	96.2	(73.0-124.3)
Female	2	1.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	8	6.1	130.6	(56.2-257.4)	Male	4	3.6	nc	(nc-nc)
Female	3	3.7	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Larynx					Testis				
Male	2	2.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	4.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	Female	6	5.5	109.5	(40.0-238.4)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	2.8	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)	Female	12	11.6	103.7	(53.5-181.1)
Lung and Bronchus					All Sites / Types				
Male	32	27.1	118.1	(80.8-166.7)	Male	204	194.2	105.0	(91.1-120.5)
Female	39	22.6	172.8	(122.9-236.3)	Female	213	178.0	119.7	(104.1-136.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	8	7.5	106.9	(46.0-210.7)	Male	4	4.8	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	2.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
Female	33	37.1	89.0	(61.2-125.0)	Female	6	3.9	154.3	(56.3-335.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	4	2.0	nc	(nc-nc)	Male	1	3.7	nc	(nc-nc)
					Female	0	1.7	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	13	12.0	108.4	(57.7-185.4)					
Female	13	11.4	114.5	(60.9-195.8)	Female	2	3.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	3	2.0	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	1.0	nc	(nc-nc)	Male	41	33.3	123.2	(88.4-167.1)
Female	0	0.8	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	3.6	nc	(nc-nc)	Male	3	2.0	nc	(nc-nc)
Female	5	2.3	219.1	(70.6-511.3)	Female	0	1.2	nc	(nc-nc)
Larynx					Testis				

Male	1	1.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	4	2.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	1.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	10	15.3	65.4	(31.3-120.3)
Female	14	13.6	102.9	(56.2-172.7)

Male	1	1.8	nc	(nc-nc)
Thyroid				
Male	0	1.1	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	7	7.0	99.7	(39.9-205.4)
All Sites / Types				
Male	102	111.5	91.5	(74.6-111.1)
Female	106	111.3	95.2	(77.9-115.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

243
Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx					
	Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)	
	Female					Female	0	0.1	nc	(nc-nc)	
Colon / Rectum						Ovary					
	Male	0	1.3	nc	(nc-nc)						
	Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)	
Esophagus						Pancreas					
	Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)	
	Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)	
Hodgkin Lymphoma						Prostate					
	Male	0	0.1	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)	
	Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)	
	Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)	
Larynx						Testis					
	Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)	
	Female	0	0.0	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	1	0.3	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)	
	Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.2	nc	(nc-nc)						
	Female	0	0.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)	
Lung and Bronchus						All Sites / Types					
	Male	1	1.6	nc	(nc-nc)	Male	6	11.1	53.9	(19.7-117.3)	
	Female	0	0.9	nc	(nc-nc)	Female	3	7.7	nc	(nc-nc)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

244

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.5	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.0	nc	(nc-nc)	Male	4	0.8	nc	(nc-nc)
Female	7	5.8	120.0	(48.1-247.3)	Female	0	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	2	2.4	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.1	nc	(nc-nc)	Male	9	6.4	141.5	(64.6-268.7)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	0	0.6	nc	(nc-nc)	Testis	Male	0	0.4	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	1	0.3	nc	(nc-nc)
Leukemia	Male	0	0.3	nc	(nc-nc)	Thyroid	Male	1	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.5	nc	(nc-nc)	Uteri Corpus and Uterus, NOS	Male	0	0.1	nc	(nc-nc)
	Female	0	0.4	nc	(nc-nc)		Female	0	0.4	nc	(nc-nc)
Lung and Bronchus	Male	0	0.3	nc	(nc-nc)	All Sites / Types	Female	2	1.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Male	23	20.5	112.0	(70.9-168.0)
	Male	2	3.0	nc	(nc-nc)		Female	15	19.4	77.5	(43.3-127.8)
	Female	0	2.6	nc	(nc-nc)						

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

245
Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	1	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma					
	Male	0	0.0	nc	(nc-nc)		Male	2	0.8	nc	(nc-nc)
	Female	3	5.3	nc	(nc-nc)		Female	1	0.5	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx					
	Female	0	0.3	nc	(nc-nc)		Male	1	0.7	nc	(nc-nc)
							Female	0	0.2	nc	(nc-nc)
Colon / Rectum						Ovary					
	Male	2	2.2	nc	(nc-nc)						
	Female	0	1.5	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)
Esophagus						Pancreas					
	Male	0	0.4	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma						Prostate					
	Male	0	0.2	nc	(nc-nc)		Male	2	6.1	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach					
	Male	0	0.6	nc	(nc-nc)		Male	0	0.4	nc	(nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.2	nc	(nc-nc)
Larynx						Testis					
	Male	0	0.3	nc	(nc-nc)		Male	1	0.3	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)						
Leukemia						Thyroid					
	Male	0	0.5	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)
	Female	1	0.3	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	0	0.3	nc	(nc-nc)						
	Female	0	0.1	nc	(nc-nc)		Female	1	1.0	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	1	2.8	nc	(nc-nc)		Male	11	20.3	54.1	(27.0-96.8)

Female	1	1.8	nc	(nc-nc)	Female	8	15.5	51.6	(22.2-101.6)
--------	---	-----	----	---------	--------	---	------	------	--------------

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

246
Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	70	58.5	119.6	(93.2-151.1)	Male	33	27.8	118.5	(81.6-166.5)
Female	25	23.6	105.8	(68.4-156.1)	Female	28	22.8	122.7	(81.5-177.3)
Brain and Other Nervous System					Multiple Myeloma				
Male	8	10.2	78.2	(33.7-154.1)	Male	6	8.0	75.1	(27.4-163.4)
Female	7	9.4	74.4	(29.8-153.3)	Female	5	7.4	67.9	(21.9-158.4)
Breast					Non-Hodgkin Lymphoma				
Male	3	1.7	nc	(nc-nc)	Male	30	27.9	107.5	(72.5-153.4)
Female	233	222.5	104.7	(91.7-119.1)	Female	23	28.3	81.1	(51.4-121.8)
Cervix Uteri					Oral Cavity & Pharynx				
Female	11	9.6	115.1	(57.4-205.9)	Male	22	20.4	107.9	(67.6-163.4)
					Female	10	11.1	89.8	(43.0-165.1)
Colon / Rectum					Ovary				
Male	105	89.3	117.6	(96.2-142.4)					
Female	84	97.8	85.9	(68.5-106.3)	Female	21	23.1	90.9	(56.3-139.0)
Esophagus					Pancreas				
Male	18	13.6	132.2	(78.3-209.0)	Male	25	16.5	151.6	(98.1-223.8)
Female	3	4.8	nc	(nc-nc)	Female	19	20.4	92.9	(55.9-145.1)
Hodgkin Lymphoma					Prostate				

Male	3	4.2	nc	(nc-nc)	Male	219	229.4	95.5	(83.3-109.0)
Female	3	3.7	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	18	21.9	82.3	(48.7-130.0)	Male	10	15.2	65.8	(31.5-120.9)
Female	13	16.0	81.3	(43.2-139.0)	Female	9	10.4	86.2	(39.3-163.7)
Larynx					Testis				
Male	10	10.0	100.4	(48.1-184.7)	Male	9	7.0	129.4	(59.0-245.6)
Female	3	2.8	nc	(nc-nc)					
Leukemia					Thyroid				
Male	16	17.2	93.0	(53.1-151.1)	Male	10	4.9	204.2	(97.7-375.5)
Female	15	15.7	95.7	(53.5-157.9)	Female	12	15.7	76.3	(39.4-133.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	8	10.2	78.6	(33.8-154.9)					
Female	6	4.6	131.8	(48.1-287.0)	Female	44	44.0	99.9	(72.6-134.1)
Lung and Bronchus					All Sites / Types				
Male	123	112.9	109.0	(90.6-130.0)	Male	808	756.8	106.8	(99.5-114.4)
Female	102	106.3	95.9	(78.2-116.4)	Female	728	758.1	96.0	(89.2-103.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

247
Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)

Brain and Other Nervous System						Multiple Myeloma				
	Male	0	0.1	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Breast						Non-Hodgkin Lymphoma				
	Male	0	0.0	nc	(nc-nc)		Male	0	0.4	nc (nc-nc)
	Female	2	2.5	nc	(nc-nc)		Female	0	0.3	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.1	nc	(nc-nc)		Male	0	0.3	nc (nc-nc)
							Female	1	0.1	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	1	1.3	nc	(nc-nc)					
	Female	1	0.8	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.2	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.1	nc	(nc-nc)		Male	4	3.4	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	0	0.3	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.1	nc (nc-nc)
Larynx						Testis				
	Male	0	0.1	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.2	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.2	nc	(nc-nc)					

Female	0	0.0	nc	(nc-nc)
Lung and Bronchus				
Male	2	1.6	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)

Female	0	0.5	nc	(nc-nc)
All Sites / Types				
Male	8	10.9	73.4	(31.6-144.6)
Female	5	7.5	66.7	(21.5-155.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

248
Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	9	7.6	118.6	(54.1-225.1)
Female	6	2.9	209.6	(76.5-456.2)
Brain and Other Nervous System				
Male	0	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	28	31.0	90.2	(59.9-130.4)
Cervix Uteri				
Female	1	1.5	nc	(nc-nc)
Colon / Rectum				
Male	11	11.8	93.2	(46.5-166.8)
Female	14	11.5	122.2	(66.8-205.0)
Esophagus				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	4.1	196.0	(84.4-386.2)
Female	3	3.3	nc	(nc-nc)
Multiple Myeloma				
Male	2	1.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	4.0	150.5	(55.0-327.6)
Female	1	3.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	3.1	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Ovary				
Female	2	3.1	nc	(nc-nc)
Pancreas				

Hodgkin Lymphoma	Male	1	1.9	nc	(nc-nc)	Prostate	Male	2	2.2	nc	(nc-nc)
	Female	1	0.6	nc	(nc-nc)		Female	2	2.4	nc	(nc-nc)
	Male	2	0.7	nc	(nc-nc)		Male	31	32.2	96.1	(65.3-136.5)
	Female	1	0.6	nc	(nc-nc)						
Kidney & Renal Pelvis	Male	5	3.2	157.3	(50.7-367.0)	Stomach	Male	1	2.0	nc	(nc-nc)
	Female	3	2.1	nc	(nc-nc)		Female	1	1.2	nc	(nc-nc)
Larynx	Male	0	1.4	nc	(nc-nc)	Testis	Male	2	1.3	nc	(nc-nc)
	Female	1	0.4	nc	(nc-nc)						
Leukemia	Male	0	2.4	nc	(nc-nc)	Thyroid	Male	1	0.8	nc	(nc-nc)
	Female	1	2.0	nc	(nc-nc)		Female	3	2.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	1.5	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
	Female	1	0.5	nc	(nc-nc)		Female	4	6.1	nc	(nc-nc)
Lung and Bronchus	Male	23	15.2	151.8	(96.2-227.7)	All Sites / Types	Male	110	105.1	104.7	(86.0-126.2)
	Female	19	13.4	141.5	(85.1-220.9)		Female	103	99.6	103.4	(84.4-125.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Bladder, Urinary						Melanoma of Skin				
Male	55	47.4	116.1	(87.5-151.1)		Male	40	26.0	154.0	(110.0-209.7)
Female	19	18.1	105.2	(63.3-164.3)		Female	18	21.4	83.9	(49.7-132.6)
Brain and Other Nervous System						Multiple Myeloma				
Male	10	10.2	98.5	(47.1-181.1)		Male	13	6.8	192.2	(102.2-328.7)
Female	15	8.6	174.7	(97.7-288.2)		Female	6	5.6	107.1	(39.1-233.2)
Breast						Non-Hodgkin Lymphoma				
Male	0	1.5	nc	(nc-nc)		Male	29	25.3	114.5	(76.7-164.5)
Female	208	198.5	104.8	(91.0-120.0)		Female	22	22.9	96.0	(60.2-145.4)
Cervix Uteri						Oral Cavity & Pharynx				
Female	13	9.7	134.6	(71.6-230.2)		Male	29	19.6	148.3	(99.3-213.0)
Colon / Rectum						Female	8	9.4	85.1	(36.6-167.7)
Male	91	73.9	123.1	(99.1-151.2)		Ovary				
Female	75	74.4	100.8	(79.3-126.3)		Female	16	20.2	79.2	(45.2-128.6)
Esophagus						Pancreas				
Male	12	11.8	101.7	(52.5-177.6)		Male	11	13.8	79.4	(39.6-142.2)
Female	5	3.7	136.9	(44.1-319.4)		Female	15	15.3	98.1	(54.9-161.8)
Hodgkin Lymphoma						Prostate				
Male	4	4.7	nc	(nc-nc)		Male	246	193.2	127.3	(111.9-144.3)
Female	4	3.8	nc	(nc-nc)		Stomach				
Kidney & Renal Pelvis						Male	13	12.7	102.1	(54.3-174.6)
Male	26	19.9	130.8	(85.4-191.7)		Female	8	8.0	100.4	(43.2-197.9)
Female	16	13.0	122.7	(70.1-199.3)		Testis				
Larynx						Male	9	8.5	106.0	(48.4-201.2)
Male	12	8.8	135.9	(70.1-237.4)		Thyroid				
Female	2	2.3	nc	(nc-nc)		Male	6	5.3	113.6	(41.5-247.3)
Leukemia										
Male	18	15.5	116.4	(68.9-184.0)						

Female	16	13.2	121.6	(69.5-197.5)
Liver and Intrahepatic Bile Ducts				
Male	5	9.3	53.9	(17.4-125.9)
Female	6	3.5	169.7	(62.0-369.5)
Lung and Bronchus				
Male	96	92.5	103.8	(84.1-126.7)
Female	96	81.9	117.2	(94.9-143.1)

Female	16	17.0	94.3	(53.9-153.2)
Uteri Corpus and Uterus, NOS				
Female	27	38.3	70.5	(46.5-102.6)
All Sites / Types				
Male	777	649.6	119.6	(111.4-128.3)
Female	648	634.9	102.1	(94.4-110.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

250
Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	2.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	9	9.7	92.8	(42.4-176.3)
Cervix Uteri				
Female	0	0.5	nc	(nc-nc)
Colon / Rectum				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.3	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.2	nc	(nc-nc)
Female	3	1.0	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Ovary				

Esophagus	Male	4	3.3	nc	(nc-nc)	Pancreas	Female	3	0.9	nc	(nc-nc)
	Female	3	2.7	nc	(nc-nc)						
Hodgkin Lymphoma	Male	1	0.6	nc	(nc-nc)	Prostate	Male	1	0.6	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis	Male	0	0.2	nc	(nc-nc)	Stomach	Male	5	9.7	51.6	(16.6-120.4)
	Female	0	0.2	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)
Larynx	Male	0	0.5	nc	(nc-nc)	Testis	Male	1	0.4	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	2	0.9	nc	(nc-nc)
Leukemia	Male	2	0.7	nc	(nc-nc)	Thyroid	Male	2	0.3	nc	(nc-nc)
	Female	1	0.5	nc	(nc-nc)		Female	2	0.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.5	nc	(nc-nc)	Uteri Corpus and Uterus, NOS					
	Female	0	0.1	nc	(nc-nc)	All Sites / Types	Female	2	1.9	nc	(nc-nc)
Lung and Bronchus	Male	4	4.3	nc	(nc-nc)		Male	25	31.2	80.2	(51.9-118.3)
	Female	5	3.4	147.6	(47.6-344.5)		Female	36	28.1	128.3	(89.8-177.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	5	3.0	166.6	(53.7-388.8)	Male	2	1.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	4	1.3	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	9	12.8	70.4	(32.1-133.6)	Female	1	1.3	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	1	0.7	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
					Female	0	0.6	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	6	4.8	125.5	(45.8-273.1)					
Female	1	3.6	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.3	nc	(nc-nc)	Male	11	13.5	81.8	(40.8-146.3)
Female	0	0.2	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	1.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Larynx					Testis				
Male	0	0.6	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)

Leukemia	Female	0	0.1	nc	(nc-nc)
	Male	4	1.0	nc	(nc-nc)
	Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Male	0	0.7	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)
Lung and Bronchus	Male	7	6.2	113.7	(45.5-234.3)
	Female	0	4.5	nc	(nc-nc)

Thyroid

Male	0	0.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)

Uteri Corpus and Uterus, NOS

Female	2	2.4	nc	(nc-nc)
--------	---	-----	----	---------

All Sites / Types

Male	40	43.7	91.5	(65.3-124.5)
Female	22	36.9	59.6	(37.3-90.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

252

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	10	5.2	192.4	(92.1-353.9)	Male	5	2.7	188.0	(60.6-438.7)
Female	1	1.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.9	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	18	17.8	101.1	(59.9-159.9)	Female	2	2.1	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				

Colon / Rectum	Female	1	0.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
	Male	6	8.0	74.6	(27.3-162.5)	Female	0	0.9	nc	(nc-nc)
Esophagus	Female	16	7.2	223.2	(127.5-362.5)	Female	2	1.8	nc	(nc-nc)
	Male	0	1.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Hodgkin Lymphoma	Female	0	0.4	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
	Male	3	0.4	nc	(nc-nc)	Male	20	21.0	95.1	(58.1-146.8)
Kidney & Renal Pelvis	Female	1	0.3	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
	Male	7	2.1	338.2	(135.5-696.8)	Female	1	0.8	nc	(nc-nc)
Larynx	Female	2	1.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
	Male	2	0.9	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Leukemia	Female	2	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
	Male	3	1.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	2	1.1	nc	(nc-nc)	Uteri Corpus and Uterus, NOS				
	Male	0	1.0	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
Lung and Bronchus	Female	1	0.3	nc	(nc-nc)	All Sites / Types				
	Male	14	10.1	138.3	(75.6-232.1)	Male	94	69.1	136.1	(110.0-166.6)
	Female	16	7.7	207.8	(118.7-337.4)	Female	77	57.8	133.3	(105.2-166.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;

- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

253
Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	95	95.8	99.1	(80.2-121.2)	Male	56	48.3	115.9	(87.5-150.5)
Female	51	40.8	124.9	(93.0-164.2)	Female	37	42.8	86.4	(60.9-119.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	19	18.0	105.3	(63.4-164.5)	Male	16	13.2	120.9	(69.0-196.3)
Female	15	16.9	88.7	(49.6-146.4)	Female	12	12.7	94.4	(48.7-165.0)
Breast					Non-Hodgkin Lymphoma				
Male	3	2.9	nc	(nc-nc)	Male	57	47.9	119.1	(90.2-154.3)
Female	396	394.8	100.3	(90.7-110.7)	Female	48	50.0	96.0	(70.8-127.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	18	18.4	97.9	(58.0-154.7)	Male	39	35.1	111.2	(79.1-152.0)
Colon / Rectum					Female	14	19.7	70.9	(38.7-119.0)
Male	168	147.3	114.1	(97.5-132.7)	Ovary				
Female	167	168.8	99.0	(84.5-115.2)	Female	35	41.1	85.2	(59.4-118.6)
Esophagus					Pancreas				
Male	19	22.8	83.4	(50.2-130.2)	Male	31	27.2	113.9	(77.4-161.7)
Female	4	8.2	nc	(nc-nc)	Female	30	35.2	85.3	(57.5-121.8)
Hodgkin Lymphoma					Prostate				
Male	10	8.5	118.1	(56.5-217.1)	Male	287	384.3	74.7	(66.3-83.8)
Female	4	7.6	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	32	37.1	86.2	(58.9-121.6)	Male	26	25.1	103.7	(67.7-152.0)

Larynx	Female	19	27.9	68.0	(40.9-106.2)
	Male	30	16.8	178.6	(120.5-254.9)
Leukemia	Female	6	4.9	122.0	(44.6-265.6)
	Male	21	29.0	72.4	(44.8-110.7)
	Female	16	27.5	58.1	(33.2-94.4)
Liver and Intrahepatic Bile Ducts					
	Male	32	17.2	186.1	(127.3-262.7)
	Female	10	7.9	126.6	(60.6-232.8)
Lung and Bronchus					
	Male	221	186.6	118.4	(103.3-135.1)
	Female	231	183.8	125.7	(110.0-142.9)

Testis	Female	23	18.1	127.1	(80.5-190.7)
	Male	12	15.8	76.0	(39.2-132.8)
Thyroid					
	Male	9	9.4	95.9	(43.8-182.1)
	Female	36	31.7	113.5	(79.5-157.2)
Uteri Corpus and Uterus, NOS					
	Female	72	77.7	92.6	(72.5-116.7)
All Sites / Types					
	Male	1275	1271.8	100.3	(94.8-105.9)
	Female	1337	1337.8	99.9	(94.7-105.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

254
Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	32	34.5	92.7	(63.4-130.9)
Female	15	13.2	114.0	(63.8-188.1)
Brain and Other Nervous System				
Male	3	6.6	nc	(nc-nc)
Female	8	5.8	138.2	(59.5-272.4)
Breast				

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	15	17.6	85.3	(47.7-140.7)
Female	10	14.5	68.9	(33.0-126.7)
Multiple Myeloma				
Male	5	4.8	103.4	(33.3-241.4)
Female	1	4.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				

Male	0	1.1	nc	(nc-nc)
Female	117	137.6	85.0	(70.3-101.9)
Cervix Uteri				
Female	4	6.4	nc	(nc-nc)
Colon / Rectum				
Male	61	53.3	114.4	(87.5-147.0)
Female	53	53.3	99.4	(74.5-130.0)
Esophagus				
Male	7	8.4	83.0	(33.2-171.0)
Female	3	2.6	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	2.9	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	9	13.8	65.1	(29.7-123.6)
Female	8	9.4	85.1	(36.6-167.7)
Larynx				
Male	6	6.3	95.7	(35.0-208.4)
Female	3	1.7	nc	(nc-nc)
Leukemia				
Male	12	10.6	113.5	(58.6-198.2)
Female	13	9.0	144.2	(76.7-246.6)
Liver and Intrahepatic Bile Ducts				
Male	6	6.4	93.6	(34.2-203.7)
Female	2	2.5	nc	(nc-nc)
Lung and Bronchus				
Male	71	68.1	104.3	(81.5-131.6)
Female	88	60.9	144.6	(116.0-178.1)

Male	15	17.3	86.5	(48.4-142.6)
Female	13	16.3	79.6	(42.3-136.1)
Oral Cavity & Pharynx				
Male	11	13.2	83.0	(41.4-148.6)
Female	10	6.7	150.2	(71.9-276.2)
Ovary				
Female	16	14.0	114.0	(65.1-185.2)
Pancreas				
Male	8	9.9	80.7	(34.7-158.9)
Female	7	11.1	63.1	(25.3-130.1)
Prostate				
Male	138	142.7	96.7	(81.3-114.3)
Stomach				
Male	10	9.0	110.6	(52.9-203.4)
Female	4	5.6	nc	(nc-nc)
Testis				
Male	7	4.9	142.3	(57.0-293.1)
Thyroid				
Male	5	3.3	149.5	(48.2-348.8)
Female	14	11.0	127.6	(69.7-214.1)
Uteri Corpus and Uterus, NOS				
Female	19	27.2	69.8	(42.0-109.0)
All Sites / Types				
Male	449	464.9	96.6	(87.8-105.9)
Female	443	447.8	98.9	(89.9-108.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

255
Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	11	11.8	93.2	(46.4-166.7)	Male	4	6.3	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	7	2.4	292.0	(117.0-601.6)	Male	1	1.7	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)	Male	10	6.1	163.7	(78.4-301.0)
Female	49	49.0	99.9	(73.9-132.1)	Female	4	5.6	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	5	2.3	217.1	(70.0-506.7)	Male	4	4.8	nc	(nc-nc)
Colon / Rectum					Female	1	2.3	nc	(nc-nc)
Male	26	18.4	141.5	(92.4-207.4)	Ovary				
Female	20	17.7	113.0	(69.0-174.5)	Female	4	4.9	nc	(nc-nc)
Esophagus					Pancreas				
Male	3	3.0	nc	(nc-nc)	Male	6	3.4	174.5	(63.7-379.8)
Female	0	0.9	nc	(nc-nc)	Female	9	3.7	245.8	(112.2-466.7)
Hodgkin Lymphoma					Prostate				
Male	3	1.0	nc	(nc-nc)	Male	68	49.7	136.7	(106.2-173.3)
Female	1	0.9	nc	(nc-nc)					

Kidney & Renal Pelvis					Stomach				
Male	6	4.9	121.7	(44.5-265.0)	Male	3	3.1	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
Larynx					Testis				
Male	0	2.2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)					
Leukemia					Thyroid				
Male	6	3.7	161.0	(58.8-350.4)	Male	1	1.2	nc	(nc-nc)
Female	5	3.1	161.2	(52.0-376.3)	Female	6	4.0	150.4	(54.9-327.3)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	5	2.3	218.3	(70.4-509.5)					
Female	0	0.8	nc	(nc-nc)	Female	9	9.7	92.9	(42.4-176.4)
Lung and Bronchus					All Sites / Types				
Male	31	23.5	131.9	(89.6-187.2)	Male	211	162.1	130.2	(113.2-149.0)
Female	26	20.8	125.0	(81.6-183.1)	Female	157	155.3	101.1	(85.9-118.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

256
Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	28	25.5	109.8	(73.0-158.7)	Male	19	13.2	143.6	(86.4-224.2)
Female	7	9.7	72.0	(28.8-148.3)	Female	19	10.8	175.2	(105.4-273.5)
Brain and Other Nervous System					Multiple Myeloma				
Male	4	5.0	nc	(nc-nc)	Male	0	3.6	nc	(nc-nc)

Breast	Female	3	4.4	nc	(nc-nc)
	Male	0	0.8	nc	(nc-nc)
Cervix Uteri	Female	137	104.2	131.4	(110.3-155.4)
	Male	7	4.8	145.2	(58.2-299.1)
Colon / Rectum	Female	48	39.3	122.1	(90.0-161.9)
	Male	32	39.5	81.1	(55.4-114.4)
Esophagus	Female	3	1.9	nc	(nc-nc)
	Male	7	6.3	111.4	(44.6-229.6)
Hodgkin Lymphoma	Female	1	1.8	nc	(nc-nc)
	Male	2	2.1	nc	(nc-nc)
Kidney & Renal Pelvis	Female	7	7.0	99.5	(39.9-205.0)
	Male	12	10.4	115.2	(59.5-201.3)
Larynx	Female	0	1.3	nc	(nc-nc)
	Male	1	4.7	nc	(nc-nc)
Leukemia	Female	3	6.8	nc	(nc-nc)
	Male	2	8.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts	Female	0	1.9	nc	(nc-nc)
	Male	4	4.9	nc	(nc-nc)
Lung and Bronchus					

Non-Hodgkin Lymphoma	Female	4	3.0	nc	(nc-nc)
	Male	12	13.0	92.4	(47.7-161.5)
Oral Cavity & Pharynx	Female	11	12.1	90.8	(45.3-162.5)
	Male	4	10.0	nc	(nc-nc)
Ovary	Female	6	5.0	120.6	(44.1-262.6)
	Male	19	10.5	180.1	(108.4-281.3)
Pancreas	Female	8	8.2	97.9	(42.1-192.9)
	Male	5	7.4	67.9	(21.9-158.5)
Prostate	Female	2	4.2	nc	(nc-nc)
	Male	102	105.8	96.4	(78.6-117.1)
Stomach	Female	2	4.2	nc	(nc-nc)
	Male	6	6.7	89.7	(32.8-195.3)
Testis	Female	4	3.6	nc	(nc-nc)
	Male	4	3.6	nc	(nc-nc)
Thyroid	Female	10	8.2	122.1	(58.4-224.5)
	Male	5	2.5	197.1	(63.5-459.9)
Uteri Corpus and Uterus, NOS	Female	24	20.5	117.2	(75.1-174.4)
	Male	24	20.5	117.2	(75.1-174.4)
All Sites / Types					

Male	45	50.5	89.1	(65.0-119.3)	Male	308	345.7	89.1	(79.4-99.6)
Female	39	45.2	86.3	(61.4-118.0)	Female	382	334.8	114.1	(102.9-126.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

257
Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	13	9.4	137.9	(73.3-235.8)	Male	8	5.4	146.9	(63.3-289.5)
Female	1	3.2	nc	(nc-nc)	Female	10	4.2	235.6	(112.8-433.2)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	2.1	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)	Male	4	5.2	nc	(nc-nc)
Female	41	40.2	102.0	(73.2-138.4)	Female	2	4.2	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	2	2.0	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Colon / Rectum					Female	0	1.8	nc	(nc-nc)
Male	13	14.9	87.0	(46.3-148.9)	Ovary				
Female	11	12.6	87.6	(43.7-156.8)	Female	2	4.0	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	2.5	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)

Hodgkin Lymphoma					Prostate				
Male	1	0.9	nc	(nc-nc)	Male	54	42.1	128.2	(96.3-167.2)
Female	1	0.7	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	10	4.3	232.6	(111.4-427.8)	Male	1	2.5	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Larynx					Testis				
Male	0	1.9	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)					
Leukemia					Thyroid				
Male	2	3.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	5	3.5	142.7	(46.0-332.9)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	2	2.0	nc	(nc-nc)					
Female	1	0.6	nc	(nc-nc)	Female	6	7.8	76.5	(27.9-166.5)
Lung and Bronchus					All Sites / Types				
Male	18	19.2	93.9	(55.6-148.3)	Male	138	135.8	101.6	(85.4-120.0)
Female	11	15.4	71.5	(35.6-127.9)	Female	104	120.6	86.2	(70.4-104.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

258
Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	81	54.2	149.5	(118.7-185.8)	Male	25	26.3	95.1	(61.6-140.5)

Female	26	20.6	126.0	(82.3-184.6)
Brain and Other Nervous System				
Male	13	9.8	132.9	(70.7-227.3)
Female	9	8.6	105.0	(47.9-199.3)
Breast				
Male	4	1.6	nc	(nc-nc)
Female	206	200.3	102.9	(89.3-117.9)
Cervix Uteri				
Female	15	9.1	164.8	(92.2-271.9)
Colon / Rectum				
Male	95	82.8	114.8	(92.8-140.3)
Female	103	85.0	121.1	(98.9-146.9)
Esophagus				
Male	12	12.7	94.8	(48.9-165.6)
Female	2	4.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	7	4.3	163.9	(65.7-337.7)
Female	11	3.7	299.0	(149.1-535.1)
Kidney & Renal Pelvis				
Male	28	20.5	136.8	(90.9-197.7)
Female	21	14.2	147.6	(91.3-225.6)
Larynx				
Male	14	9.3	150.7	(82.3-252.9)
Female	7	2.5	275.5	(110.4-567.6)
Leukemia				
Male	20	16.2	123.7	(75.5-191.1)
Female	16	14.0	114.4	(65.3-185.8)
Liver and Intrahepatic Bile Ducts				

Female	22	21.2	103.7	(65.0-157.0)
Multiple Myeloma				
Male	6	7.4	80.9	(29.5-176.0)
Female	9	6.5	139.1	(63.5-264.0)
Non-Hodgkin Lymphoma				
Male	26	26.3	99.0	(64.6-145.0)
Female	29	25.2	114.9	(76.9-165.1)
Oral Cavity & Pharynx				
Male	21	19.1	110.2	(68.2-168.5)
Female	8	10.0	80.1	(34.5-157.9)
Ovary				
Female	22	20.8	105.9	(66.3-160.3)
Pancreas				
Male	23	15.3	150.6	(95.4-225.9)
Female	30	17.7	169.1	(114.1-241.5)
Prostate				
Male	158	213.5	74.0	(62.9-86.5)
Stomach				
Male	26	14.1	184.6	(120.5-270.5)
Female	13	9.1	143.3	(76.2-245.1)
Testis				
Male	10	7.5	132.6	(63.5-243.8)
Thyroid				
Male	9	4.8	186.5	(85.1-354.1)
Female	14	15.4	90.9	(49.6-152.5)
Uteri Corpus and Uterus, NOS				

Male	16	9.5	168.7	(96.4-274.0)					
Female	2	4.0	nc	(nc-nc)	Female	40	39.7	100.8	(72.0-137.3)
Lung and Bronchus					All Sites / Types				
Male	146	104.9	139.1	(117.5-163.6)	Male	783	706.6	110.8	(103.2-118.8)
Female	122	93.9	130.0	(107.9-155.2)	Female	783	676.4	115.8	(107.8-124.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

259

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	2.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	11	8.7	126.8	(63.2-226.9)	Female	0	0.9	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.4	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
					Female	0	0.4	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	5	3.6	138.5	(44.6-323.1)					
Female	1	3.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)

Esophagus						Pancreas					
Male	0	0.6	nc	(nc-nc)		Male	0	0.7	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)	
Hodgkin Lymphoma						Prostate					
Male	1	0.2	nc	(nc-nc)		Male	9	10.2	88.3	(40.3-167.5)	
Female	0	0.1	nc	(nc-nc)							
Kidney & Renal Pelvis						Stomach					
Male	0	1.0	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)	
Female	0	0.6	nc	(nc-nc)		Female	0	0.3	nc	(nc-nc)	
Larynx						Testis					
Male	0	0.4	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)	
Female	0	0.1	nc	(nc-nc)							
Leukemia						Thyroid					
Male	0	0.7	nc	(nc-nc)		Male	0	0.2	nc	(nc-nc)	
Female	0	0.5	nc	(nc-nc)		Female	0	0.6	nc	(nc-nc)	
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
Male	1	0.4	nc	(nc-nc)							
Female	0	0.1	nc	(nc-nc)		Female	1	1.8	nc	(nc-nc)	
Lung and Bronchus						All Sites / Types					
Male	4	4.7	nc	(nc-nc)		Male	26	31.9	81.6	(53.3-119.6)	
Female	2	3.7	nc	(nc-nc)		Female	18	26.9	67.0	(39.7-106.0)	

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	6	4.1	147.2	(53.8-320.5)	Male	3	2.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	10	17.3	57.9	(27.7-106.5)	Female	0	1.8	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.9	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
					Female	0	0.8	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	6	6.5	92.7	(33.8-201.7)					
Female	4	5.2	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Esophagus					Pancreas				
Male	1	1.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	1	0.4	nc	(nc-nc)	Male	14	17.8	78.7	(43.0-132.1)
Female	0	0.3	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	2	1.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Larynx					Testis				
Male	1	0.8	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
Leukemia					Thyroid				

Male	1	1.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	0	0.9	nc	(nc-nc)					
Female	0	0.3	nc	(nc-nc)	Female	6	3.3	181.4	(66.2-394.9)
Lung and Bronchus					All Sites / Types				
Male	10	8.2	122.2	(58.5-224.7)	Male	48	58.6	82.0	(60.4-108.7)
Female	7	6.3	110.9	(44.4-228.5)	Female	48	51.1	93.9	(69.2-124.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

261
Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	23	16.4	140.5	(89.0-210.8)	Male	19	8.7	218.7	(131.6-341.6)
Female	4	6.6	nc	(nc-nc)	Female	6	7.6	78.8	(28.8-171.4)
Brain and Other Nervous System					Multiple Myeloma				
Male	2	3.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	5	3.1	163.3	(52.6-381.2)	Female	1	2.1	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)	Male	8	8.5	93.7	(40.3-184.6)
Female	72	70.6	101.9	(79.8-128.4)	Female	7	8.4	83.7	(33.5-172.5)
Cervix Uteri					Oral Cavity & Pharynx				
					Male	11	6.5	170.4	(84.9-304.9)
Female	3	3.4	nc	(nc-nc)	Female	2	3.4	nc	(nc-nc)

Colon / Rectum						Ovary				
Male	30	25.4	118.2	(79.7-168.7)						
Female	23	26.7	86.0	(54.5-129.1)		Female	5	7.2	69.5	(22.4-162.1)
Esophagus						Pancreas				
Male	6	4.0	148.6	(54.3-323.5)		Male	5	4.7	105.9	(34.1-247.1)
Female	0	1.3	nc	(nc-nc)		Female	6	5.6	107.8	(39.4-234.7)
Hodgkin Lymphoma						Prostate				
Male	2	1.6	nc	(nc-nc)		Male	58	68.2	85.1	(64.6-110.0)
Female	0	1.4	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	5	6.8	74.1	(23.9-172.8)		Male	5	4.3	116.8	(37.6-272.6)
Female	6	4.8	124.6	(45.5-271.2)		Female	1	2.8	nc	(nc-nc)
Larynx						Testis				
Male	5	3.0	166.0	(53.5-387.4)		Male	0	2.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)						
Leukemia						Thyroid				
Male	5	5.3	94.6	(30.5-220.8)		Male	4	1.7	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)		Female	8	5.9	135.1	(58.2-266.1)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	3	3.1	nc	(nc-nc)						
Female	1	1.3	nc	(nc-nc)		Female	13	13.9	93.4	(49.7-159.8)
Lung and Bronchus						All Sites / Types				
Male	51	32.6	156.4	(116.4-205.6)		Male	260	224.4	115.9	(102.2-130.9)
Female	41	31.0	132.2	(94.8-179.3)		Female	222	229.1	96.9	(84.6-110.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Obs	Exp	SIR	95% CI	Obs	Exp	SIR	95% CI
-----	-----	-----	--------	-----	-----	-----	--------

Bladder, Urinary						Melanoma of Skin				
Male	7	11.3	62.0	(24.8-127.8)		Male	1	5.3	nc	(nc-nc)
Female	5	4.7	107.1	(34.5-249.9)		Female	4	4.5	nc	(nc-nc)
Brain and Other Nervous System						Multiple Myeloma				
Male	0	1.9	nc	(nc-nc)		Male	2	1.6	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)		Female	2	1.5	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	1	0.3	nc	(nc-nc)		Male	2	5.3	nc	(nc-nc)
Female	42	44.9	93.6	(67.4-126.5)		Female	4	5.5	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	3	4.0	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)		Female	2	2.2	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	9	17.3	52.2	(23.8-99.0)						
Female	12	19.4	61.8	(31.9-108.0)		Female	3	4.6	nc	(nc-nc)
Esophagus						Pancreas				
Male	3	2.6	nc	(nc-nc)		Male	3	3.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)		Female	2	4.0	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	2	0.7	nc	(nc-nc)		Male	32	43.8	73.0	(49.9-103.1)
Female	0	0.6	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	4.2	nc	(nc-nc)		Male	3	3.0	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)		Female	3	2.1	nc	(nc-nc)
Larynx						Testis				

Male	0	1.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	4	3.2	nc	(nc-nc)
Female	6	3.0	197.7	(72.2-430.3)
Liver and Intrahepatic Bile Ducts				
Male	3	2.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Lung and Bronchus				
Male	10	21.5	46.6	(22.3-85.7)
Female	19	20.8	91.3	(55.0-142.6)

Male	0	1.0	nc	(nc-nc)
Thyroid				
Male	1	0.9	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	10	8.9	112.9	(54.1-207.7)
All Sites / Types				
Male	96	144.6	66.4	(53.8-81.0)
Female	132	150.4	87.8	(73.4-104.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

263
Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0.0	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)

Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Colon / Rectum						Ovary				
	Male	1	0.9	nc	(nc-nc)					
	Female	2	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Esophagus						Pancreas				
	Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Larynx						Testis				
	Male	0	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.2	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
	Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.1	nc	(nc-nc)					
	Female	0	0.0	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	1	1.1	nc	(nc-nc)	Male	7	7.8	90.0	(36.1-185.5)
	Female	1	0.9	nc	(nc-nc)	Female	7	6.3	111.7	(44.7-230.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);

- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

264
Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	7	4.3	161.0	(64.5-331.7)	Male	3	2.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	5	2.5	202.3	(65.2-472.1)
Female	15	19.7	76.0	(42.5-125.4)	Female	5	2.1	234.9	(75.7-548.3)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	1.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
					Female	1	0.9	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	6	6.9	87.3	(31.9-189.9)					
Female	8	6.6	121.9	(52.5-240.2)	Female	5	2.0	254.1	(81.9-592.9)
Esophagus					Pancreas				
Male	4	1.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				
Male	0	0.5	nc	(nc-nc)	Male	21	18.3	114.5	(70.8-175.0)
Female	0	0.4	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				

Larynx	Male	1	2.0	nc	(nc-nc)	Testis	Male	2	1.2	nc	(nc-nc)
	Female	1	1.2	nc	(nc-nc)		Female	1	0.7	nc	(nc-nc)
	Male	0	0.9	nc	(nc-nc)		Male	0	0.8	nc	(nc-nc)
	Female	0	0.2	nc	(nc-nc)						
Leukemia	Male	1	1.5	nc	(nc-nc)	Thyroid	Male	0	0.6	nc	(nc-nc)
	Female	3	1.2	nc	(nc-nc)		Female	1	1.8	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS					
	Male	1	0.9	nc	(nc-nc)						
	Female	0	0.3	nc	(nc-nc)		Female	0	3.7	nc	(nc-nc)
Lung and Bronchus						All Sites / Types					
	Male	10	8.6	116.0	(55.5-213.4)		Male	69	61.8	111.6	(86.8-141.3)
	Female	5	7.5	67.1	(21.6-156.6)		Female	60	60.4	99.3	(75.8-127.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

265
Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	2	1.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)

Breast						Non-Hodgkin Lymphoma				
	Male	0	0.0	nc	(nc-nc)		Male	1	0.6	nc (nc-nc)
	Female	2	4.3	nc	(nc-nc)		Female	0	0.5	nc (nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
	Female	0	0.2	nc	(nc-nc)		Male	1	0.5	nc (nc-nc)
							Female	0	0.2	nc (nc-nc)
Colon / Rectum						Ovary				
	Male	3	1.9	nc	(nc-nc)					
	Female	3	1.5	nc	(nc-nc)		Female	0	0.4	nc (nc-nc)
Esophagus						Pancreas				
	Male	0	0.3	nc	(nc-nc)		Male	0	0.3	nc (nc-nc)
	Female	0	0.1	nc	(nc-nc)		Female	0	0.3	nc (nc-nc)
Hodgkin Lymphoma						Prostate				
	Male	0	0.1	nc	(nc-nc)		Male	5	4.9	101.1 (32.6-236.0)
	Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis						Stomach				
	Male	1	0.5	nc	(nc-nc)		Male	0	0.3	nc (nc-nc)
	Female	1	0.3	nc	(nc-nc)		Female	0	0.2	nc (nc-nc)
Larynx						Testis				
	Male	1	0.2	nc	(nc-nc)		Male	0	0.2	nc (nc-nc)
	Female	0	0.0	nc	(nc-nc)					
Leukemia						Thyroid				
	Male	0	0.4	nc	(nc-nc)		Male	0	0.1	nc (nc-nc)
	Female	0	0.3	nc	(nc-nc)		Female	0	0.4	nc (nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
	Male	0	0.2	nc	(nc-nc)					
	Female	0	0.1	nc	(nc-nc)		Female	1	0.8	nc (nc-nc)
Lung and Bronchus						All Sites / Types				
	Male	0	2.3	nc	(nc-nc)		Male	14	16.4	85.2 (46.5-142.9)

Female 3 1.7 nc (nc-nc)

Female 11 13.5 81.6 (40.7-145.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

266
Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	0	1.5	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Brain and Other Nervous System					Multiple Myeloma				
Male	1	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Breast					Non-Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	5	6.2	80.9	(26.1-188.9)	Female	1	0.7	nc	(nc-nc)
Cervix Uteri					Oral Cavity & Pharynx				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
					Female	0	0.3	nc	(nc-nc)
Colon / Rectum					Ovary				
Male	7	2.4	286.7	(114.9-590.7)					
Female	1	2.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Esophagus					Pancreas				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma					Prostate				

Male	0	0.2	nc	(nc-nc)	Male	7	6.7	103.9	(41.6-214.1)
Female	0	0.1	nc	(nc-nc)					
Kidney & Renal Pelvis					Stomach				
Male	0	0.7	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Larynx					Testis				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)					
Leukemia					Thyroid				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts					Uteri Corpus and Uterus, NOS				
Male	1	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Lung and Bronchus					All Sites / Types				
Male	4	3.1	nc	(nc-nc)	Male	24	22.0	109.2	(69.9-162.5)
Female	3	2.4	nc	(nc-nc)	Female	18	18.8	95.7	(56.7-151.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

267
Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1998-2002

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
Bladder, Urinary					Melanoma of Skin				
Male	4	4.7	nc	(nc-nc)	Male	5	2.8	178.3	(57.5-416.1)
Female	1	1.6	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)

Brain and Other Nervous System						Multiple Myeloma				
Male	2	1.2	nc	(nc-nc)		Male	1	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)		Female	0	0.5	nc	(nc-nc)
Breast						Non-Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)		Male	2	2.7	nc	(nc-nc)
Female	27	20.0	135.0	(88.9-196.4)		Female	3	2.1	nc	(nc-nc)
Cervix Uteri						Oral Cavity & Pharynx				
						Male	1	2.1	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)		Female	0	0.9	nc	(nc-nc)
Colon / Rectum						Ovary				
Male	2	7.5	nc	(nc-nc)						
Female	7	6.4	109.3	(43.8-225.2)		Female	1	2.0	nc	(nc-nc)
Esophagus						Pancreas				
Male	1	1.2	nc	(nc-nc)		Male	2	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)		Female	1	1.3	nc	(nc-nc)
Hodgkin Lymphoma						Prostate				
Male	1	0.5	nc	(nc-nc)		Male	17	19.8	85.8	(50.0-137.4)
Female	1	0.4	nc	(nc-nc)						
Kidney & Renal Pelvis						Stomach				
Male	3	2.1	nc	(nc-nc)		Male	1	1.3	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)		Female	0	0.7	nc	(nc-nc)
Larynx						Testis				
Male	1	0.9	nc	(nc-nc)		Male	2	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)						
Leukemia						Thyroid				
Male	4	1.7	nc	(nc-nc)		Male	0	0.6	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)		Female	4	2.0	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts						Uteri Corpus and Uterus, NOS				
Male	0	1.0	nc	(nc-nc)						

Lung and Bronchus	Female	0	0.3	nc	(nc-nc)	All Sites / Types	Female	6	3.8	158.6	(57.9-345.3)
	Male	6	9.3	64.3	(23.5-140.0)		Male	57	67.3	84.7	(64.1-109.7)
	Female	14	7.4	188.8	(103.1-316.8)		Female	74	60.9	121.5	(95.4-152.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;